Switchpoint Bio, a Helsinki- and Cambridge, Massachusetts-based biotech startup, raised €4.75 million (US$5.3 million) in Pre-Seed financing. Treehouse Delmar Investments provided €4.48 million (US$5 million) of the total. The company develops a blood-based epigenomic platform for drug developers.
Use of proceeds
The startup emerged from stealth earlier this year. The new capital will support expansion of clinical and biobank datasets. It will also fund further development of its epigenomic and AI platform.
Founding team
Switchpoint Bio was founded in 2025 by Samuel Myllykangas and Jason Buenrostro. Myllykangas previously built and scaled Blueprint Genetics, which Quest Diagnostics acquired in 2020. Buenrostro is a Harvard professor, Broad Institute epigenomics program director, and inventor of ATAC-seq.
What the platform does
Circulating immune cells carry epigenomic marks of disease, exposures, and treatment. The company combines precision epigenomic profiling and AI to read that record from blood. This may give drug developers an earlier view of mechanism, response, and resistance.
Switchpoint Bio is now moving into clinical and industry validation. Early testing focuses on autoimmune disease, including systemic lupus erythematosus. The company also plans to grow its scientific and technical team across Helsinki and Cambridge.